DK1853285T3 - Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia - Google Patents

Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia

Info

Publication number
DK1853285T3
DK1853285T3 DK06734085.1T DK06734085T DK1853285T3 DK 1853285 T3 DK1853285 T3 DK 1853285T3 DK 06734085 T DK06734085 T DK 06734085T DK 1853285 T3 DK1853285 T3 DK 1853285T3
Authority
DK
Denmark
Prior art keywords
amyloid deposits
activated microglia
involving activated
brain
inflammation associated
Prior art date
Application number
DK06734085.1T
Other languages
English (en)
Inventor
Beka Solomon
Orna Goren
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of DK1853285T3 publication Critical patent/DK1853285T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK06734085.1T 2005-02-01 2006-01-31 Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia DK1853285T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64838305P 2005-02-01 2005-02-01
PCT/US2006/003291 WO2006083795A1 (en) 2005-02-01 2006-01-31 Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia

Publications (1)

Publication Number Publication Date
DK1853285T3 true DK1853285T3 (da) 2011-06-27

Family

ID=36589064

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06734085.1T DK1853285T3 (da) 2005-02-01 2006-01-31 Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia

Country Status (13)

Country Link
US (3) US7867487B2 (da)
EP (1) EP1853285B1 (da)
JP (1) JP5096169B2 (da)
CN (1) CN101166536B (da)
AT (1) ATE501723T1 (da)
CY (1) CY1111455T1 (da)
DE (1) DE602006020697D1 (da)
DK (1) DK1853285T3 (da)
ES (1) ES2363203T3 (da)
PL (1) PL1853285T3 (da)
PT (1) PT1853285E (da)
SI (1) SI1853285T1 (da)
WO (1) WO2006083795A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324554A1 (en) * 2006-07-21 2009-12-31 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates
US20110182948A1 (en) 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
AU2009316326A1 (en) * 2008-11-24 2010-05-27 Ramot At Tel-Aviv University Ltd. Method for treating Parkinson' s disease using filamentous bacteriophage
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
EP2736522A1 (en) * 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
HK1198627A1 (zh) 2011-08-05 2015-05-22 Neurophage Pharmaceuticals, Inc. 纯丝状噬菌体及其制备方法
US9493515B2 (en) * 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EP2825201A4 (en) * 2012-03-15 2015-12-09 Univ Ramot FILAMENTOUS BACTERIOPHAGE AS ANGIOGENESIS MODULATOR
US9655933B2 (en) 2012-03-15 2017-05-23 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage as an angiogenesis modulator
EA033666B1 (ru) 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
JP2016526044A (ja) * 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ， インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
AU2003205623A1 (en) * 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates

Also Published As

Publication number Publication date
EP1853285A2 (en) 2007-11-14
WO2006083795A8 (en) 2007-03-15
CY1111455T1 (el) 2015-08-05
HK1110790A1 (en) 2008-07-25
CN101166536A (zh) 2008-04-23
US8361458B2 (en) 2013-01-29
PT1853285E (pt) 2011-06-06
CN101166536B (zh) 2012-06-27
US20090180991A1 (en) 2009-07-16
JP5096169B2 (ja) 2012-12-12
ATE501723T1 (de) 2011-04-15
EP1853285B1 (en) 2011-03-16
JP2008528688A (ja) 2008-07-31
ES2363203T3 (es) 2011-07-26
SI1853285T1 (sl) 2011-07-29
PL1853285T3 (pl) 2011-08-31
WO2006083795A1 (en) 2006-08-10
US20110142803A1 (en) 2011-06-16
US20130177533A1 (en) 2013-07-11
US7867487B2 (en) 2011-01-11
DE602006020697D1 (de) 2011-04-28

Similar Documents

Publication Publication Date Title
CY1111455T1 (el) Μεθοδος για θεραπεια φλεγμονης που συνδυαζεται με αποθεσεις αμυλοειδους και φλεγμονη εγκεφαλου που περιλαμβανει ενεργοποιημενη μικρογλοια
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
GT200800098A (es) Anticuerpos anti mn y metodos para su utilización
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
PL372372A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
EA200900492A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
TW200728466A (en) Antibody molecules having specificity for human IL-6
PH12016500302A1 (en) Compositions and method for treating complement-associated conditions
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
NO20065252L (no) Behandling av forstyrrelser
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
TW200507840A (en) Method of treating multiple myeloma
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي
EA200702078A1 (ru) Способ обработки и строительства скважин
EA200870263A1 (ru) Внутривенный способ лечения вирусной инфекции